IMCR Immunocore Holdings plc

41.25
-8.06  -16%
Previous Close 49.31
Open 49.15
52 Week Low 39.02
52 Week High 61.9899
Market Cap $1,744,697,790
Shares 42,295,704
Float 42,295,704
Enterprise Value $2,042,851,464
Volume 112,034
Av. Daily Volume 118,293
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Tebentafusp
Uveal melanoma
BLA Filing
BLA Filing
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
IMC-C103C
Solid tumors
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
IMC-F106C
Solid tumors
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
GSK01
Synovial sarcoma
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. OXFORDSHIRE, England and CONSHOHOCKEN, Pa. and ROCKVILLE, Md., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Immunocore (NASDAQ:IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM).

    Bahija Jallal, Chief Executive Officer of Immunocore, said: "We are delighted that the FDA has granted Breakthrough Therapy Designation for tebentafusp

    OXFORDSHIRE, England and CONSHOHOCKEN, Pa. and ROCKVILLE, Md., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Immunocore (NASDAQ:IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM).

    Bahija Jallal, Chief Executive Officer of Immunocore, said: "We are delighted that the FDA has granted Breakthrough Therapy Designation for tebentafusp based on the survival benefit from our Phase 3 clinical trial announced in November 2020. There is an urgent need for an approved treatment for this rare and aggressive form of melanoma and we look forward to continuing to work with regulators to bring tebentafusp to patients as quickly as possible."

    In an initial pre-planned interim analysis of a randomized Phase 3 clinical trial (IMCgp100-202) in previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies, tebentafusp demonstrated superior overall survival (OS) benefit as a monotherapy. The primary endpoint was achieved when the OS Hazard Ratio (HR) in the intent-to-treat population favored tebentafusp, HR=0.51 (95% CI: 0.36, 0.71); p< 0.0001, over investigator's choice (82% pembrolizumab; 12% ipilimumab; 6% dacarbazine).

    The Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).

    Tebentafusp has also been granted Fast Track Designation and orphan drug designation from the FDA for uveal melanoma and Promising Innovative Medicine designation under the UK Early Access to Medicines Scheme. Immunocore will be working with the FDA to facilitate submission of a BLA for tebentafusp. If approved, Immunocore believes tebentafusp would be the first new therapy for the treatment of metastatic uveal melanoma in 40 years.

    About Immunocore

    Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore's most advanced oncology therapeutic candidate, tebentafusp, has demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.

    About ImmTAC® Molecules

    Immunocore's proprietary T cell receptor (TCR) technology generates a novel class of bispecific biologics called ImmTAC (Immune mobilising monoclonal TCRs Against Cancer) molecules that are designed to redirect the immune system to recognise and kill cancerous cells. ImmTAC molecules are soluble TCRs engineered to recognise intracellular cancer antigens with ultra-high affinity and selectively kill these cancer cells via an anti-CD3 immune-activating effector function. Based on the demonstrated mechanism of T cell infiltration into human tumours, the ImmTAC mechanism of action holds the potential to treat hematologic and solid tumours, regardless of mutational burden or immune infiltration, including immune "cold" low mutation rate tumours. 

    About Tebentafusp

    Tebentafusp is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma, and is the first molecule developed using Immunocore's ImmTAC technology platform designed to redirect and activate T cells to recognise and kill tumour cells. Tebentafusp has been granted Breakthrough Therapy Designation, Fast Track designation and orphan drug designation by the FDA in the United States and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. For more information about enrolling tebentafusp clinical trials for metastatic uveal melanoma, please visit ClinicalTrials.gov (NCT03070392).

    About Uveal Melanoma

    Uveal melanoma is a rare and aggressive form of melanoma, which affects the eye. Metastatic uveal melanoma typically has a poor prognosis and has no currently accepted optimal management or treatment. Although it is the most common primary intraocular malignancy in adults, the diagnosis is rare, with approximately 8,000 new patients diagnosed globally each year (1,600-2,000 cases per year in the United States). Up to 50% of people with uveal melanoma will eventually develop metastatic disease. When the cancer spreads beyond the eye, only approximately half of patients will survive for one year.

    Forward Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but are not limited to, statements regarding the efficacy, safety and therapeutic potential of tebentafusp, the results, conduct, progress and timing of the Company's development programs including tebentafusp, the potential benefit of Breakthrough Therapy Designation for tebentafusp, estimates regarding the planned submission a BLA for tebentafusp and the regulatory approval path for tebentafusp. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company's control. These risks and uncertainties include, but are not limited to, the impacts of the COVID-19 pandemic on the Company's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; and the uncertainties and timing of the regulatory approval process. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in in the Company's final prospectus dated February 4, 2021 filed with the Securities and Exchange Commission pursuant to Rule 424(b)(4) on February 8, 2021, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information except as required by law.



    CONTACT: 
    
    Immunocore 
    Debra Nielsen, Head of Communications
    T: +1 (610) 368-8602
    E:  
    Follow on Twitter: @Immunocore
    
    Consilium Strategic Communications (corporate and financial)
    Mary-Jane Elliott/ Chris Welsh/ Sukaina Virji 
    T: +44 (0)203 709 5700
    E: 
    
    Investor Relations
    Clayton Robertson, Head of Investor Relations
    T: +1 215-384-4781
    E: 

    Primary Logo

    View Full Article Hide Full Article
  2. PRESS RELEASE

    Immunocore announces key appointments to management and Board

    Ralph Torbay appointed Head of Commercial to spearhead the launch of tebentafusp

    Dr. Roy S. Herbst appointed as a Non-Executive Director to the Board

    OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US – 16 February 2021 – Immunocore Holdings plc (NASDAQ:IMCR), (or the "Company" or "Immunocore"), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announces the appointment of Ralph Torbay as its new Head of Commercial and the appointment of Dr. Roy S. Herbst as a member…

    PRESS RELEASE

    Immunocore announces key appointments to management and Board

    Ralph Torbay appointed Head of Commercial to spearhead the launch of tebentafusp

    Dr. Roy S. Herbst appointed as a Non-Executive Director to the Board

    OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US – 16 February 2021 – Immunocore Holdings plc (NASDAQ:IMCR), (or the "Company" or "Immunocore"), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announces the appointment of Ralph Torbay as its new Head of Commercial and the appointment of Dr. Roy S. Herbst as a member of its Board of Directors, effective January 28, 2021. 

    Ralph Torbay is an experienced commercial leader with a proven track record of successful oncology launches and an extensive background in strategy, marketing, sales and sales management. Over the past four years, Ralph has launched three major drugs in oncology and helped to build the commercial Haematology franchise at AstraZeneca. At AstraZeneca, Ralph led the global commercial launch of IMFINZI®, the first checkpoint inhibitor therapy for stage III lung cancer, and launched Tagrisso®, which, at the time, was one of the fastest product launches and uptake in lung cancer to date. In his role as the Global Haematology Head of Marketing at AstraZeneca, Ralph was tasked with building the Haematology commercial organization while launching CALQUENCE®. Previously, Ralph led and worked on several high-profile pipeline integrations and product launches at Novartis Oncology, including GLEEVEC®, TASIGNA®, ARZERRA® and FARYDAK®. Ralph received his Master of Business Administration from Simon Graduate School of Business, University of Rochester, Rochester, NY and his Bachelor of Science in Biotechnology from Rochester Institute of Technology, Rochester, NY. Ralph will be developing and implementing Immunocore's commercial strategy. He will be based in Immunocore's Rockville, Maryland office.

    Roy Herbst joined the Immunocore Board of Directors in January. He previously served as a member of Immunocore's Scientific Advisory Board (SAB) and is internationally recognized for his leadership and expertise as a physician-scientist in lung cancer treatment and research. He is currently Ensign Professor of Medicine (Medical Oncology), Professor of Pharmacology, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital. In 2020, Roy was awarded the Distinguished Public Service Award for Exceptional Leadership in Cancer Science Policy by the American Association for Cancer Research. He is also a member of the Board of Directors of the American Association for Cancer Research, the International Association for the Study of Lung Cancer and Shanghai Junshi Biosciences Co., Ltd., and is a member of the Thoracic Malignancy Steering Committee at the National Cancer Institute.

    Bahija Jallal, Chief Executive Officer of Immunocore, said: "Ralph brings a wealth of industry experience to Immunocore with a proven track record in global commercial success through the launch of several high-profile products. His expertise will be instrumental as we prepare for the commercial launch of tebentafusp, our lead ImmTAC product candidate for the treatment of patients with metastatic uveal melanoma.

    "I would also like to welcome Roy to Immunocore's Board of Directors. Roy is an expert in the field and has been a trusted advisor to the Company for many years. I am delighted to have him join our Board where we believe his extensive scientific background and expertise in cancer treatment and research will be invaluable as we implement our strategy."

    Ralph Torbay, Head of Commercial at Immunocore, said: "The impressive quality of data already published for tebentafusp clearly demonstrates its potential as a new breakthrough treatment for metastatic uveal melanoma patients, an underserved group where new therapies are urgently needed. This is a testament to the excellence of Immunocore's pioneering science and underlines the potential of our bispecific immunotherapies across a range of indications. I am very much looking forward to being part of the team advancing tebentafusp and other future potential Immunocore products with the aim of transforming patients' lives."

    Dr. Roy S. Herbst, Non-Executive Director of Immunocore, said: "It has been my pleasure to work on Immunocore's SAB over the past few years and I am pleased to have this opportunity to work even more closely with the team at Board level as we reach a critical and exciting stage in the Company's development."

    - Ends -

    About Immunocore

    Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore's most advanced oncology therapeutic candidate, tebentafusp, has demonstrated monotherapy activity in a Phase 2 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies, and is currently being studied in an ongoing Phase 3 clinical trial.

    For more information, please contact:

    Immunocore

    Debra Nielsen, Head of Communications

    T: +1 (610) 368-8602

    E:

    Follow on Twitter: @Immunocore

    Consilium Strategic Communications (corporate and financial)

    Mary-Jane Elliott/ Chris Welsh/ Sukaina Virji

    T: +44 (0)203 709 5700

    E:

    Investor Relations  

    Clayton Robertson, Head of Investor Relations

    T: +1 215-384-4781

    E:



    Primary Logo

    View Full Article Hide Full Article
  3. PRESS RELEASE

    Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0 Million Concurrent Private Placement

    OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US – 9 February 2021 – Immunocore Holdings plc (NASDAQ:IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced the closing of its previously announced initial public offering in the United States of 11,426,280 American Depositary Shares ("ADSs") representing…

    PRESS RELEASE

    Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0 Million Concurrent Private Placement

    OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US – 9 February 2021 – Immunocore Holdings plc (NASDAQ:IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced the closing of its previously announced initial public offering in the United States of 11,426,280 American Depositary Shares ("ADSs") representing 11,426,280 ordinary shares, including the exercise in full by the underwriters of their option to purchase an additional 1,490,384 ADSs, at an initial public offering price of $26.00 per ADS. The gross proceeds to Immunocore from the offering were approximately $297.1 million. All ADSs sold in the offering were offered by Immunocore.

    Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Jefferies LLC acted as joint book-running managers for the offering.

    In addition to the ADSs sold in the public offering, Immunocore announced the completion of the concurrent sale of an additional 576,923 ADSs at the initial offering price of $26.00 per ADS, for gross proceeds of approximately $15.0 million, in a private placement to the Bill & Melinda Gates Foundation. The sale of these ADSs was not registered under the Securities Act of 1933, as amended, and the ADSs are subject to a 180-day lock-up agreement. 

    A registration statement relating to these securities became effective on February 4, 2021. The offering was made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained from any of the joint book-running managers for the offering:  Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 866-471-2526, facsimile: 212-902-9316, e-mail: ; J.P. Morgan Securities LLC,  c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at +1 866 803 9204 or by email at ; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at +1 877 821 7388 or by email at . For the avoidance of doubt, such prospectus will not constitute a "prospectus" for the purposes of the Regulation (EU) 2017/1129 and has not been reviewed by any competent authority in any member state in the European Economic Area or the United Kingdom.

    A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the "SEC"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

    In any member state of the European Economic Area (the "EEA") this announcement and any offering are only addressed to and directed at persons who are "qualified investors" ("Qualified Investors") within the meaning of the Prospectus Regulation (Regulation (EU) 2017/1129). In the United Kingdom, this announcement and any offering are only addressed to and directed at persons who are "qualified investors" within the meaning of the UK Prospectus Regulation (Regulation (EU) 2017/1129 as if forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018) (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), (ii) high net worth entities who fall within Article 49(2)(a) to (d) of the Order, or (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as "relevant persons").

    This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, relevant persons, and (ii) in any member state of the EEA, Qualified Investors.

    About Immunocore

    Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore's most advanced oncology therapeutic candidate, tebentafusp, has demonstrated monotherapy activity in a Phase 2 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies, and is currently being studied in an ongoing Phase 3 clinical trial.

    ##

    Contacts:

    Immunocore

    Media

    Debra Nielsen, Head of Communications

    T: +1 (610) 368-8602

    E:

    Consilium Strategic Communications (corporate and financial)

    Mary-Jane Elliott/ Chris Welsh/ Sukaina Virji

    T: +44 (0)203 709 5700

    E:

    Investor Relations  

    E:



    Primary Logo

    View Full Article Hide Full Article
  4. PRESS RELEASE

    Immunocore Announces Pricing of Upsized Initial Public Offering

    OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US – 4 February 2021 – Immunocore Holdings plc (NASDAQ:IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced the pricing of its upsized initial public offering in the United States of 9,935,896 American Depositary Shares ("ADSs") representing 9,935,896 ordinary shares at an initial public offering price of $26.00 per ADS, for total gross proceeds of approximately $258.3 million. All ADSs sold in the offering…

    PRESS RELEASE

    Immunocore Announces Pricing of Upsized Initial Public Offering

    OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US – 4 February 2021 – Immunocore Holdings plc (NASDAQ:IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced the pricing of its upsized initial public offering in the United States of 9,935,896 American Depositary Shares ("ADSs") representing 9,935,896 ordinary shares at an initial public offering price of $26.00 per ADS, for total gross proceeds of approximately $258.3 million. All ADSs sold in the offering were offered by Immunocore. The ADSs are expected to begin trading on The Nasdaq Global Select Market on February 5, 2021 under the ticker symbol "IMCR." In addition, Immunocore has granted the underwriters a 30-day option to purchase up to an additional 1,490,384 ADSs at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on or about February 9, 2021, subject to customary closing conditions.

    Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Jefferies LLC are acting as joint book-running managers for the offering.

    A registration statement relating to these securities became effective on February 4, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from any of the joint book-running managers for the offering:  Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 866-471-2526, facsimile: 212-902-9316, e-mail: ; J.P. Morgan Securities LLC,  c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at +1 866 803 9204 or by email at ; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at +1 877 821 7388 or by email at . For the avoidance of doubt, such prospectus will not constitute a "prospectus" for the purposes of the Regulation (EU) 2017/1129 and has not been reviewed by any competent authority in any member state in the European Economic Area or the United Kingdom.

    A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the "SEC"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

    In any member state of the European Economic Area (the "EEA") this announcement and any offering are only addressed to and directed at persons who are "qualified investors" ("Qualified Investors") within the meaning of the Prospectus Regulation (Regulation (EU) 2017/1129). In the United Kingdom, this announcement and any offering are only addressed to and directed at persons who are "qualified investors" within the meaning of the UK Prospectus Regulation (Regulation (EU) 2017/1129 as if forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018) (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), (ii) high net worth entities who fall within Article 49(2)(a) to (d) of the Order, or (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as "relevant persons").

    This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, relevant persons, and (ii) in any member state of the EEA, Qualified Investors.

    About Immunocore

    Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore's most advanced oncology therapeutic candidate, tebentafusp, has demonstrated monotherapy activity in a Phase 2 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies, and is currently being studied in an ongoing Phase 3 clinical trial.

    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements with regard to Immunocore' expectations regarding the commencement of trading of ADSs on The Nasdaq Global Select Market and the completion of the proposed securities offering. Words such as "anticipates," "believes," "expects," "intends," "projects," "anticipates," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed securities offering discussed above will be consummated on the terms described or at all. Completion of the proposed offering and the terms thereof are subject to numerous factors, many of which are beyond the control of Immunocore, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in Immunocore's filings with the SEC. Immunocore undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

    ##

    Contacts:

    Immunocore

    Media

    Debra Nielsen, Head of Communications

    T: +1 (610) 368-8602

    E:

    Consilium Strategic Communications (corporate and financial)

    Mary-Jane Elliott/ Chris Welsh/ Sukaina Virji

    T: +44 (0)203 709 5700

    E:

    Investor Relations  

    E:



    Primary Logo

    View Full Article Hide Full Article
View All Immunocore Holdings plc News